Despite its concentrated biotechnology focus, the iShares Biotechnology ETF carries a lower beta of 0.72 than the Invesco S&P 500 Equal Weight Health Care ETF’s 0.78.
That counterintuitive volatility gap sits at the center of a debate growing among investors who want healthcare exposure but face a meaningful choice in how to get it.
The iShares fund posted a one-year return of 35.5% as of October 15, 2026, outpacing the Invesco equal-weight fund’s already solid 31.9% gain over the same period.
For income-oriented investors, however, the picture tilts differently, with RSPH delivering a dividend yield of 0.6% compared to IBB’s relatively thin 0.2%.
The two funds also differ sharply in size, with IBB commanding $10.5 billion in assets under management against RSPH’s considerably smaller $904.7 million.
That asset gap reflects the broader investor appetite for targeted biotech exposure, a segment that has attracted significant capital as drug development pipelines have matured across the industry.
On cost, the difference is narrow but real: RSPH charges an expense ratio of 0.40%, slightly undercutting IBB’s 0.44%, a distinction that compounds meaningfully over a long holding period.
RSPH tracks the broader S&P 500 healthcare universe using an equal-weighting methodology, spreading risk across the sector rather than concentrating it in the largest names.
IBB, by contrast, uses a market-cap-weighted approach with a specific focus on biotechnology, meaning the largest companies in the biotech space command the heaviest influence on performance.
Investors prioritizing recent momentum and a lower beta reading may find IBB’s profile more compelling, while those seeking income and wider sector diversification have a credible case for RSPH.
The expense ratio advantage at RSPH is modest, but combined with its higher dividend yield, it presents a different value proposition from the raw-return story IBB tells.
With healthcare remaining one of the most structurally resilient sectors in the broader market, both funds offer distinct pathways depending on how an investor weighs growth, income, and concentration risk.
